Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.
Matthias GrieseStefano CostaRachel W LinnemannMarcus Alexander MallEdward F McKoneDeepika PolineniBradley S QuonFelix C C RingshausenJennifer L Taylor-CousarNicholas J WithersSamuel M MoskowitzCori L DainesPublished in: American journal of respiratory and critical care medicine (2021)